

## **Drug Safety Oversight Board Roster**

### **Chair (Non-voting)**

- Douglas Throckmorton, M.D., Deputy Director for Regulatory Programs  
Center for Drug Evaluation and Research

### **Acting Executive Director (Non-voting)**

- Terry Toigo, RPh, MBA  
Acting Executive Director of the Drug Safety Oversight Board, Associate Director for Drug  
Safety Operations, Center for Drug Evaluation and Research

### **Center for Drug Evaluation and Research**

#### Primary Member:

- Robert Temple, M.D., Deputy Director for Clinical Science
- Richard Moscicki, M.D., Deputy Director of Science Operations

### **Office of New Drugs, Center for Drug Evaluation and Research**

#### Primary Members:

- Mwango Kashoki, M.D., M.P.H., Associate Director for Safety, Office of New Drugs
- Mary Parks, M.D., Director, Division of Metabolism and Endocrinology Products

#### Alternate Members:

- John Jenkins, M.D., Director, Office of New Drugs
- Sandra Kweder, M.D., Deputy Director, Office of New Drugs
- Ellis Unger, M.D., Director, Office of Drug Evaluation 1

### **Office of Medical Policy, Center for Drug Evaluation and Research**

- Patrick Archdeacon, M.D., Medical Officer
- Richard A. Araujo, Pharm. D. MS, CDR USPHS, Deputy Director, OMP

### **Office of Generic Drugs, Center for Drug Evaluation and Research**

#### Primary Member:

- Linda Forsyth, M.D., Division of Clinical Review

#### Alternate Member:

- Shewit Bezabeh

### **Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research**

#### Primary Members:

- Mark I. Avigan, M.D., Associate Director for Critical Path Initiatives,

#### Alternate Member :

- Gerald DalPan, M.D., M.H.S., Director

### **Office of Pharmacovigilance and Epidemiology**

#### **Primaries :**

- Judy Staffa, Ph.D., R.Ph., Acting Associate Director for Regulatory Research
- Culin Wang, M.D., Director of Epidemiology I
- Robert Levin, M.D., Acting Director, Division of Pharmacovigilance I
- Scott Proestel, M.D., Director, Division of Pharmacovigilance II

#### **Alternate :**

- Solomon Iyasu, M.D., Director, Office of Pharmacovigilance and Epidemiology

### **Office of Medication Error Prevention and Risk Management**

#### **Primary Members:**

- Todd Bridges, RPh, Deputy Director
- Cynthia LaCivita, RPh, Acting Director, Division of Risk Management

#### **Alternate Members:**

- Kellie Taylor, PharmD, Deputy Director
- Claudia Manzo, PharmD, Acting Director

### **Office of Translational Sciences, Center for Drug Evaluation and Research**

#### **Immediate Office**

#### **Primary Member:**

- TBD

#### **Alternate Member:**

- ShaAvhree Buckman, M.D., Ph.D., F.A.A.P. Acting Director, Office of Translational Sciences

### **Office of Biostatistics**

#### **Primary Member:**

- Aloka Chakravarty, Ph.D., Director, Division of Biometrics

#### **Alternate Member:**

- Mark Levenson, Ph.D., Deputy Director, Division of Biostatistics\_7

### **Office of Clinical Pharmacology**

#### **Primary Member:**

- Darrell Abernethy, M.D., Ph.D., Associate Director of Drug Safety, Office of Clinical Pharmacology

#### **Alternate Member:**

- Keith K. Burkhart, M.D., FACMT, Senior Advisor for Medical Toxicology Predictive Safety Team

**Office of Communications**

Primary Member:

- Kimberly A. Rawlings, Acting Director

Alternate Member:

- Mary E. Kremzner, PharmD, MPH, CAPT, USPHS, Acting Deputy, Office of Communications

**Office of Compliance, (CDER)**

Primary Member:

- Ilisa B.G. Bernstein, Pharm. D., J.D., Acting Deputy Director, Office of Compliance

Alternate Member:

- Charles E. Lee, M.D.,CAPT, USPHS, Div. of New Drugs and Labeling Compliance, Office of Compliance

**Office of the Center Director, Center for Drug Evaluation and Research**

Primary Member:

- John Whyte, MD, MPH, Director of Professional Affairs and Stakeholder Engagement, Office of the Center Director

Alternate Member:

**Office of Pharmaceutical Science, Center for Drug Evaluation and Research**

Primary Member:

- Samia M. Nasr, R.Ph. M.S.

Alternate Member:

TBD

**Center for Biologics Evaluation and Research, Food and Drug Administration**

Primary Member:

- Steven Anderson, Ph.D.,M.P.P., Acting Director, Office of Biostatistics

Alternate Member:

- David Martin, MD., M.P.H., Acting Director, Division of Epidemiology, Office of Biostatistics and Epidemiology

**Center for Devices and Radiological Health, Food and Drug Administration**

Primary Member:

- Kimberly Brown Smith, MD, PhD, Office of Compliance, Clinical Team Leader

Alternate Member:

- Robert L. Becker, Jr., M.D., Ph.D., Chief Medical Officer, Office of In Vitro Diagnostic Device Evaluation and Safety

## **Federal Partners**

### **Agency for Healthcare Research and Quality**

#### Primary Member:

- Scott R. Smith, Ph.D., Director, Pharmaceutical Outcomes Research, Center for Outcomes and Evidence
- Alternate Member: TBD

### **Centers for Medicare and Medicaid Services**

#### Primary Member:

- Jeffrey A. Kelman, M.D., MMsc., Chief Medical Officer

#### Alternate Members:

- Judith A. Geisler, R.Ph., CHC, Director, Division of Formulary and Benefit Operations
- Monica Reed, PharmD., LT, USPHS, Division of Formulary and Benefit Operations

### **Centers for Disease Control and Prevention**

#### Primary Member:

- Dan Budnitz, M.D., M.P.H., CAPT, USPHS, Director, Medication Safety Program, Division of Healthcare Quality Promotion

#### Alternate Member:

- Nadine Shehab, PharmD., M.P.H., Division of Healthcare of Quality Promotion

### **Department of Defense**

#### Primary Member:

- William G. Davies, RPh., MS, Integrated Utilization Branch Chief, Pharmacy Operations Division, Defense Health Agency
- COL Trinko Coster, MD, MS, Director, Pharmacovigilance Center, Office of the Surgeon General, Department of the Army

### **Department of Defense (Clinical)**

#### Primary Member:

- Walter M. Downs, MD, CAPT MC USN, Medical Consultant, Rheumatologist, Pharmacy Operations Division

#### Alternate Member:

- Michael Datena, CIV, OASD (HA) / TMA, Acting Assistant Chief of the Patient Safety Division
- Deborah Myers, RPh, MBA, Deputy Director, Patient Safety Analysis Center, Tricare Management Activity

## **Health Resources and Services Administration**

### Primary Member:

- Karen C. Williams, MBA, Pharm.D., Sr Program Mgmt Officer, Office of Pharmacy Affairs

### Alternate Member:

- Lawrence Momodu, Pharm.D., LT, USPHS, Office of Pharmacy Affairs

## **Indian Health Service**

### Primary Member:

- Ryan Schupbach, Pharm. D., BCPS,CACP,NCPS, Commander, U.S., Public Health Service, Clinical Pharmacy Director & National Anticoagulation Training Program Director

### Alternate Member:

- Matthew R. Baker, Pharm.D, BCPS, CDR United States Public Health Service, Supervisor Pharmacy Support Branch, IHS, National Supply Service Center

## **National Institutes of Health, National Cancer Institute**

### Primary Member:TBD

### Alternate Member:

- Pamela Jo Harris, M.D.,F.A.C.P., Senior Investigator, Investigational Drug Branch, Cancer Therapy Evaluation Program

## **National Institute of Health, Office of Director**

### Primary Member:

- Jacqueline Corrigan-Curay, M.D., J.D., Acting Director, Office of Biotechnology Activities

### Alternate Member: TBD

## **Department of Veterans Affairs**

### Primary Member:

- C. Bernie Good, M.D., M.P.H., Chairman, Medical Advisory Panel for Pharmacy Benefits Management, Veterans Administration Pittsburgh Healthcare System

### Alternate Members:

- Peter Glassman, MBBS, M.Sc., Staff Physician, Department of Veterans Affairs, VA Greater Los Angeles Healthcare System
- Walid F. Gellad, M.D., M.P.H., Department of Veterans Affairs, Veterans Administration Pittsburgh Healthcare System

## **Bureau of Prisons**

### Primary Member:

- RADM Chris Bina, PharmD, U.S. Assistant Surgeon General, Director, Pharmacy Program, Federal Bureau of Prisons, Health Services Division

### Alternate Member:

- A. Martin Johnston, R.Ph.,Captain, US Public Health Service Chief, Pharmacy Logistic Support, Federal Bureau of Prisons, Health Services Division